Latest Innovation News

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

TG Metals Limited has achieved over 90% gold recovery in heap leach testwork on its Laterite resource at the Van Uden Gold Project, advancing preparations for a final investment decision in Q3 2026.

Advanced Energy Minerals is ramping up its Quebec high purity alumina plant to 3,000 tpa by mid-2026, with plans to double capacity to 6,000 tpa by 2029 amid a tightening global market and supply deficit.

Delorean Corporation has banked a $5.76 million cash refund from the Australian Government’s FY2025 R&D Tax Incentive, underpinning its bioenergy infrastructure growth. Another refund linked to FY2026 expenditure is anticipated next year.

Bayan Mining and US Critical Materials have signed a non-binding MoU to develop rare-earth processing technologies licensed from the Colorado School of Mines, targeting high-grade mineralisation at the Sheep Creek Project in Montana. The collaboration aims to support a US-based rare earth supply chain with potential strategic investment on the horizon.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.

FirstWave Cloud Technology delivered a strong Q3 FY26 with a $1.40m net operating cash inflow and a major two-year licensing agreement with Mexico’s Banobras bank, marking a key milestone in its AI compliance pivot.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.